[Enucleations, eviscerations and orbital implants in German eye hospitals].
Schuh A. et al, (2024), Ophthalmologie
Relevance of genetic testing in the gene-targeted trial era: the Rostock Parkinson's disease study.
Westenberger A. et al, (2024), Brain, 147, 2652 - 2667
Applications of Nanopore sequencing in precision cancer medicine.
Dyshlovoy SA. et al, (2024), Int J Cancer
The impact of inversions across 33,924 families with rare disease from a national genome sequencing project.
Pagnamenta AT. et al, (2024), Am J Hum Genet, 111, 1140 - 1164
Somatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AML.
Risueño A. et al, (2024), Leuk Res, 140
What is new in the 5th edition of the World Health Organization classification of mature B and T/NK cell tumors and stromal neoplasms?
Attygalle AD. et al, (2024), J Hematop
Effect of Compression Dressing After Upper Eyelid Blepharoplasty on Edema, Ecchymosis, Pain and Ocular Surface Irritation.
Schuh A. et al, (2024), Ophthalmic Plast Reconstr Surg
The 5th edition of the World Health Organization Classification of mature lymphoid and stromal tumors - an overview and update.
Attygalle AD. et al, (2024), Leuk Lymphoma, 65, 413 - 429
Exclusion of persistent mutations in splicing factor genes and isocitrate dehydrogenase 2 improves the prognostic power of molecular measurable residual disease assessment in acute myeloid leukemia.
Murphy T. et al, (2024), Haematologica, 109, 671 - 675
Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease.
Munir T. et al, (2023), N Engl J Med
Structural and non-coding variants increase the diagnostic yield of clinical whole genome sequencing for rare diseases.
Pagnamenta AT. et al, (2023), Genome Med, 15
RAS-pathway mutations are common in patients with ruxolitinib refractory/intolerant myelofibrosis: molecular analysis of the PAC203 cohort.
O'Sullivan JM. et al, (2023), Leukemia
Special edition of the Seminars in Hematology series on Global Hematology Care.
Schuh A., (2023), Semin Hematol
Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study.
Shadman M. et al, (2023), Clin Lymphoma Myeloma Leuk, 23, 515 - 526
Venetoclax ramp-up strategies for chronic lymphocytic leukaemia in the United Kingdom: a real world multicentre retrospective study.
Figueroa-Mora R. et al, (2023), Br J Haematol, 202, 48 - 53